In brief
- A team at Northeastern University (Boston) tested psilocybin on female rats subjected to mild, repetitive head impacts—a model mimicking concussions from sports or accidents.
- A dose of psilocybin following each impact reduced cerebral edema, restored blood flow closer to normal levels, and lowered phosphorylated tau, a protein linked to neurodegenerative diseases.
- According to the authors, this is the first published experimental study testing psilocybin as a treatment for traumatic brain injury; for now, it remains limited to animal models.
Each year, approximately 2.9 million people in the United States suffer a traumatic brain injury, with 70 to 90 percent classified as mild. When these impacts are repeated—such as in contact sports or military service—the risk of long-term sequelae increases, yet no approved treatment exists to prevent them. A study published in Communications Biology, part of the Nature portfolio, explores whether psilocybin might change that, at least within an animal model.
One hit daily for three consecutive days
The team, led by Craig Ferris, utilized a model that required no surgery or deep anesthesia: middle-aged female rats (nine months old) received one mild head impact per day for three consecutive days while awake and in their active phase, mimicking how such injuries occur in humans. The model causes no fractures or hemorrhages, only the swelling typical of a bump. Thirty minutes after each impact, half of the animals received an injection of psilocybin (3 mg/kg, the dose that activated the brain most effectively in a previous study by the group), while the other half received saline. A third group, which received no impacts, served as a healthy control. Each group consisted of eight animals; part of the experiment was repeated with older rats (eighteen months old) to see if aging altered the response.
Less damage, more signs of repair
Using magnetic resonance imaging and molecular analysis, rats treated with psilocybin showed less edema than the untreated, injured group, and their vascular response to carbon dioxide—which is typically impaired by trauma—approached normal levels. Functional connectivity between brain regions, reduced by the injury, was recovered, and in some comparisons, it even surpassed that of the uninjured animals. Psilocybin also reduced phosphorylated tau, which is associated with Alzheimer’s disease and chronic traumatic encephalopathy when present in excess, and increased brain-derived neurotrophic factor (BDNF) and its receptor TrkB, both of which are linked to neuronal repair. In the older rats, researchers observed double the amount of myelin—the substance that protects nerve fibers—in the corpus callosum and the sensorimotor cortex. Behavioral test results were more modest: while there were improvements in the expected direction, several differences did not reach statistical significance.
Implications
The authors emphasize that, prior to this work, there were no published experimental studies on psilocybin as a treatment for brain injury. It is important not to get ahead of ourselves: these are rats, not humans, and the behavioral changes were minor and less clear than the cerebral and molecular findings. The design itself, involving an injection thirty minutes after the impact, is difficult to translate directly to an emergency room or a sports locker room. In parallel, and unrelated to this specific study, clinical trials are already underway using psilocybin for people with persistent concussion symptoms; Monash University in Australia launched one such trial earlier this year. These are distinct paths that, if confirmed by further research, could eventually converge.
Source
- Brengel, E. K. et al. Psilocybin as a treatment for repetitive mild head injury: evidence from neuroradiology and molecular biology. Communications Biology (Nature Portfolio), September 8, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
